Liu Xinkuan, Shao Wenyi, Luo Mingyi, Bian Jiayin, Yu Deng-Guang
School of Material Science and Engineering, University of Shanghai for Science and Technology, Shanghai 200093, China.
Nanomaterials (Basel). 2018 Mar 22;8(4):184. doi: 10.3390/nano8040184.
Nanomaterials providing sustained release profiles are highly desired for efficacious drug delivery. Advanced nanotechnologies are useful tools for creating elaborate nanostructure-based nanomaterials to achieve the designed functional performances. In this research, a modified coaxial electrospinning was explored to fabricate a novel core-sheath nanostructure (nanofibers F2), in which a sheath drug-free gliadin layer was successfully coated on the core ketoprofen (KET)-gliadin nanocomposite. A monolithic nanocomposite (nanofibers F1) that was generated through traditional blending electrospinning of core fluid was utilized as a control. Scanning electron microscopy demonstrated that both nanofibers F1 and F2 were linear. Transmission electron microscopy verified that nanofibers F2 featured a clear core-sheath nanostructure with a thin sheath layer about 25 nm, whereas their cores and nanofibers F1 were homogeneous KET-gliadin nanocomposites. X-ray diffraction patterns verified that, as a result of fine compatibility, KET was dispersed in gliadin in an amorphous state. In vitro dissolution tests demonstrated that the thin blank nanocoating in nanofibers F2 significantly modified drug release kinetics from a traditional exponential equation of nanofibers F1 to a zero-order controlled release model, linearly freeing 95.7 ± 4.7% of the loaded cargoes over a time period of 16 h.
提供缓释特性的纳米材料对于有效的药物递送非常有必要。先进的纳米技术是创建基于精细纳米结构的纳米材料以实现设计功能性能的有用工具。在本研究中，探索了一种改进的同轴静电纺丝方法来制备一种新型的核壳纳米结构（纳米纤维F2），其中在核酮洛芬（KET）-麦醇溶蛋白纳米复合材料上成功包覆了一层无药物的麦醇溶蛋白鞘层。通过传统的核流体共混静电纺丝制备的整体纳米复合材料（纳米纤维F1）用作对照。扫描电子显微镜表明纳米纤维F1和F2都是线性的。透射电子显微镜证实纳米纤维F2具有清晰的核壳纳米结构，鞘层薄约25nm，而它们的核以及纳米纤维F1是均匀的KET-麦醇溶蛋白纳米复合材料。X射线衍射图谱证实，由于良好的相容性，KET以无定形状态分散在麦醇溶蛋白中。体外溶出试验表明，纳米纤维F2中的薄空白纳米涂层显著改变了药物释放动力学，从纳米纤维F1的传统指数方程转变为零级控释模型，在16小时的时间段内线性释放95.7±4.7%的负载药物。
